Clinical Trials

Phase 2 Not yet recruiting

Multiple Myeloma

NCT06948084 2026-03-18

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

80 enrolled

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07479979 2026-03-18

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

62 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT03798678 2026-03-17

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

36 enrolled

Phase 3 Active not recruiting

Multiple Myeloma

NCT05552976 2026-03-17

SUCCESSOR-2

525 enrolled

Multiple Myeloma, Recurrence

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Multiple Myeloma, Recurrence

NCT05438043 2026-03-16

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

30 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT05050097 2026-03-13

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

380 enrolled

Multiple Myeloma

NCT07391657 2026-03-12

DURGA-4

508 enrolled

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

Phase 2 Recruiting

30 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT05434689 2026-03-05

COMMANDER

80 enrolled

Phase 3 Active not recruiting

Multiple Myeloma

NCT03729804 2026-03-04

(COBRA)

250 enrolled

Multiple Myeloma

NCT04933539 2026-02-27

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

14 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

39 enrolled

Multiple Myeloma

NCT04973605 2026-02-20

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

246 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT01297764 2026-02-19

QUAD

17 enrolled

Phase 1 Not yet recruiting

Multiple Myeloma

NCT07082270 2026-02-19

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

21 enrolled

Multiple Myeloma

NCT05199311 2026-02-18

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

66 enrolled

Multiple Myeloma

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

440 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms

NCT05572515 2026-02-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Phase 1 Terminated

35 enrolled 10 charts

Multiple Myeloma, Plasmacytoma

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

302 enrolled 38 charts 1 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03275285 2026-02-09

IKEMA

Phase 3 Completed

Multiple Myeloma

NCT04113018 2026-02-03

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

39 enrolled 16 charts

Multiple Myeloma

NCT05497804 2026-02-03

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

17 enrolled

Multiple Myeloma

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04430894 2026-01-29

KRDI in Transplant-Eligible MM

50 enrolled 20 charts

Multiple Myeloma

NCT05556616 2026-01-29

iinnovate-2

Phase 1 Terminated

15 enrolled 15 charts

Multiple Myeloma

NCT05675449 2026-01-26

MagnetisMM-20

Phase 1 Recruiting

90 enrolled

Multiple Myeloma, Recurrence

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1 Recruiting

317 enrolled

Multiple Myeloma

NCT04822337 2026-01-20

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

70 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02969837 2026-01-16

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Phase 2 Completed

46 enrolled 10 charts

Multiple Myeloma

NCT05675319 2026-01-05

AlloRelapseMM

Phase 3 Terminated

28 enrolled

Multiple Myeloma

NCT05704049 2025-12-29

IZALCO

118 enrolled

Multiple Myeloma

NCT01665794 2025-12-22

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

25 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT05789303 2025-12-22

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2 Recruiting

83 enrolled